| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | NaN | 0* | NaN | 0 |
| Cost of revenues | NaN | 0* | NaN | 0 |
| Gross profit | NaN | 0 | NaN | 0 |
| Gain on lease termination | NaN | 0 | NaN | NaN |
| Research and development | 1,915,000 | 676,000 | 1,035,000 | 1,136,000 |
| General and administrative | 1,631,000 | 1,419,000 | 958,000 | 1,365,000 |
| Impairment of goodwill | 2,044,000 | NaN | NaN | NaN |
| Total operating expenses | 5,590,000 | 2,095,000 | 1,993,000 | 2,501,000 |
| Loss from operations | -5,590,000 | -2,095,000 | -1,993,000 | -2,501,000 |
| Change in fair value of convertible notes | NaN | 0* | NaN | NaN |
| Change in fair value to bridge notes derivative liability | NaN | 0* | NaN | NaN |
| Change in fair value of contingent consideration | NaN | 0* | NaN | 0 |
| Forward Sales Contract Expense | NaN | 1,495,750* | NaN | -512,000 |
| Other income, net | NaN | 479,000 | -6,000 | -123,000 |
| Change in fair value of warrant liabilities | NaN | 500* | NaN | 0 |
| Losss Gaines On Extinguishment Of Debt | NaN | -1,402,000* | 734,000 | NaN |
| Interest income | NaN | 20,750* | NaN | NaN |
| Interest income, net | 44,000 | -63,000 | 31,000 | 0 |
| Total other income (expense), net | 44,000 | 530,000 | 759,000 | -635,000 |
| Loss before income taxes | -5,546,000 | -1,565,000 | -1,234,000 | -3,136,000 |
| Benefit (provision) for income taxes | -40,000 | -62,000 | 6,000 | 3,000 |
| Net loss | -5,506,000 | -1,503,000 | -1,240,000 | -3,139,000 |
| Series a preferred stock dividend | NaN | 8,000 | NaN | 8,000 |
| Net loss attributable to common stockholders | NaN | -1,511,000 | -1,240,000 | -3,147,000 |
| Basic EPS | -6.95 | -0.24 | -0.15 | -0.61 |
| Diluted EPS | -6.95 | -0.24 | -0.15 | -0.61 |
| Basic Average Shares | 792,000 | 6,307,000* | 8,226,000 | 5,179,000 |
| Diluted Average Shares | 792,000 | 6,307,000* | 8,226,000 | 5,179,000 |
Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc. (ERNA)